GlaxoSmithKline's shingles shot scores in 16,000-patient study

GlaxoSmithKline ($GSK) is one step closer to challenging Merck's ($MRK) Zostavax vaccine. Glaxo rolled out data from a hefty Phase III study showing that its shingles-fighting candidate cut the risk of that disease by 97.2% in adults aged 50 and older, compared with placebo. Report

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.